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INTRODUCTION 
COVID-19 has caused millions of deaths worldwide, and 
hundreds of millions of people have been infected with the 
causative agent, SARS-CoV-2 (1). Large cohort studies have 
shown that increased age, being a male, and various comor-
bidities, such as obesity, cardiovascular disease, hyperten-
sion, and chronic lung diseases, associate with poor outcomes 
(2–4). Pre-existing immunity against SARS-CoV-2 may also 
modulate the severity of COVID-19 (5). 
Several studies have reported the existence of functional 
T cell responses in the peripheral blood of SARS-CoV-2-
unexposed individuals that cross-recognize SARS-CoV-2 (6–
14). Cross-reactive SARS-CoV-2-specific memory (m)CD4+ T 
cells are readily detectable ex vivo in approximately 20–50% 
of unexposed people and become almost universally detecta-
ble after in vitro expansion (6), whereas cross-reactive SARS-
CoV-2-specific mCD8+ T cells are much less common. These 
pre-existing cellular immune responses are likely generated 
by previous infections with common cold human corona-
viruses (HCoVs), which share considerable sequence homol-
ogy with SARS-CoV-2 (12), although other pathogens have 
also been implicated in this phenomenon (15, 16). 
Pre-existing T cell immunity associates with negative (6) 
and positive effects on the development of adaptive responses 
against SARS-CoV-2 (17, 18). However, these studies are lim-
ited to analyses of peripheral blood samples, and cross-reac-
tive T cells would likely need to be positioned at sites of viral 
entry to limit the severity of COVID-19. Immune surveillance 
is maintained by specialized T cells that recirculate between 
tissues and the intravascular space via the lymphatic system 
(19), whereas anatomically localized immunity is primarily a 
function of tissue-resident memory T (TRM) cells (20), which 
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that SARS-CoV-2-specific memory CD4+ T cells could be found at similar frequencies in the tonsils and 
peripheral blood in unexposed individuals, whereas functional SARS-CoV-2-specific memory CD8+ T cells 
were almost only detectable in the tonsils. Tonsillar SARS-CoV-2-specific memory CD8+ T cells displayed a 
follicular homing and tissue-resident memory phenotype, similar to tonsillar Epstein-Barr virus-specific 
memory CD8+ T cells, but were functionally less potent than other virus-specific memory CD8+ T cell 
responses. The presence of pre-existing tissue-resident memory CD8+ T cells in unexposed individuals 
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remain in situ and act as frontline defenders against patho-
gen invasion (21). TRM cells constitutively express CD69 alone 
or in combination with CD103 and/or CD49a, all of which en-
sure tissue retention via different mechanisms (22–24). How-
ever, little is known about the function, phenotype, or even 
the existence of SARS-CoV-2-specific TRM cells in unexposed 
individuals. This is an important knowledge gap in the light 
of growing evidence suggesting that TRM cells are critical me-
diators of protection against viral diseases (25–27). 
In this study, we conducted a flow cytometric survey of 
virus-specific T cell responses in oropharyngeal (tonsillar) 
lymphoid tissue and matched peripheral blood samples col-
lected from children and adults before the onset of the cur-
rent pandemic in 2019. Our results provide new information 
regarding the function, phenotype, and tissue compartmen-
talization of pre-existing mCD4+ and mCD8+ T cells directed 
against SARS-CoV-2, with potentially important implications 
for heterologous immune responses. 
RESULTS 
SARS-CoV-2-specific mCD8+ T cells preferentially lo-
calize to oropharyngeal lymphoid tissue in unexposed 
individuals 
To optimize assays for the detection of virus-specific 
mCD4+ and mCD8+ T cell responses in the upper respiratory 
tract, we first compared the expression of activation-induced 
markers (AIMs) on the cell surface (PD-L1, CD25, 
CD134/OX40, and CD137/4-1BB) or the intracellular expres-
sion of AIMs (4-1BB and CD154/CD40L) and cytokines (TNF-
α and IFN-γ) in the absence or presence of virus peptide stim-
ulation (Figs. S1 and S2). AIMs are dynamically regulated 
among circulating T cells and minimally expressed at base-
line (10, 28–30). In contrast, we found that AIMs were com-
monly expressed among tonsillar T cells in the absence of 
peptide stimulation (Fig. S2A–C), precluding the use of these 
markers alone for the reliable identification of infrequent an-
tigen-specific responses (Fig. S2D, E), whereas the corre-
sponding background levels of intracellular cytokines were 
negligible (Fig. S2A–C). We therefore used a combination of 
intracellular CD40L and TNF-α to identify mCD4+ T cell re-
sponses and a combination of intracellular 4-1BB and IFN-γ 
to identify mCD8+ T cell responses (Fig. S2D, E). 
Tonsil samples were obtained from children (n=40) and 
adults (n=41) who underwent surgical intervention for ob-
structive sleep apnea at least one year before the emergence 
of COVID-19 (Table S1). Cells were stimulated with overlap-
ping peptide pools spanning the spike, nucleocapsid, mem-
brane, envelope, ORF1a, ORF1b, and ORF3–10 proteins of 
SARS-CoV-2 and selected immunodominant proteins en-
coded by Epstein-Barr virus (EBV), cytomegalovirus (CMV), 
or HCoV-OC43 (Fig. 1A, Fig. S3A). Antigen-specific mCD8+ T 
cell responses directed against all four viruses were readily 
detected in tonsil samples, based on the concurrent up-
regulation of intracellular 4-1BB and IFN-γ (Fig. 1A–D). 
SARS-CoV-2-specific mCD8+ T cells occurred at lower fre-
quencies compared with EBV-specific and CMV-specific 
mCD8+ T cells (Fig. 1B, C) but were nonetheless detected in 
26 of the 81 donors (32%) (Fig. 1D). In line with a lack of clear 
immunodominance patterns in peripheral blood samples (10, 
11), these tonsillar mCD8+ T cell responses were directed 
against multiple proteins derived from SARS-CoV-2 (Fig. 1B–
D). Tonsil samples commonly harbored mCD8+ T cells spe-
cific for EBV (76%) and CMV (53%) but less commonly har-
bored mCD8+ T cells specific for the seasonal HCoV-OC43 
(28%) (Fig. 1D). Among tonsil samples with detectable mCD8+ 
T cell responses against SARS-CoV-2, 50% showed reactivity 
against a single antigen, and <25% showed reactivity against 
more than two antigens (Fig. 1A, Fig. S3B). Stimulation indi-
ces were correlated positively among different SARS-CoV-2 
antigens, and ORF1b-specific and/or ORF3–10-specific re-
sponses correlated positively with those directed against 
EBV, CMV, and HCoV-OC43 (Fig. 1E). The latter also demon-
strated a positive correlation with responses directed against 
EBV and CMV (Fig. 1E). 
Tonsillar mCD4+ T cell responses directed against SARS-
CoV-2 were detected in a subset of individuals, based on the 
concurrent up-regulation of intracellular CD40L and TNF-α 
(Fig. S4A–D). Higher background expression of these mark-
ers was observed among tonsillar mCD4+ T cells compared 
with tonsillar mCD8+ T cells in some individuals, likely re-
flecting greater levels of basal activation and effectively rais-
ing the detection threshold for antigen-specific responses 
(Figs. 1A and S4A). Despite these limitations, we detected 
SARS-CoV-2-reactive mCD4+ T cell responses in 32% of tonsil 
samples (Fig. S4E), and in total, we detected SARS-CoV-2-
reactive mCD4+ and/or mCD8+ T cell responses in 49% of ton-
sil samples (Fig. S4F). 
Cross-reactive SARS-CoV-2-specific mCD4+ T cell re-
sponses appear to be more common in peripheral blood than 
cross-reactive SARS-CoV-2-specific mCD8+ T cell responses 
(6–11). Our analysis suggested SARS-CoV-2-specific mCD4+ 
and mCD8+ T cells were present at similar frequencies in 
SARS-CoV-2-unexposed oropharyngeal lymphoid tissue (Fig. 
S4F). To address this potential discrepancy, we compared vi-
rus-specific mCD4+ and mCD8+ T cell responses in matched 
tonsil and peripheral blood samples from a subset of donors 
in our cohort. SARS-CoV-2-specific mCD4+ T cells were de-
tected at similar frequencies in both compartments (Fig. 
S4G), whereas SARS-CoV-2-specific mCD8+ T cells were de-
tected almost exclusively in the tonsils (Figs. 1F–H). EBV-
specific mCD8+ T cells were also found predominantly in the 
tonsils (Fig. 1G), whereas CMV-specific T cells were mainly 
found in the circulation (Fig. 1G), as described previously (31–
33). This approach enabled the sensitive detection of virus-
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that SARS-CoV-2-reactive mCD8+ T cells were preferentially 
localized to the tonsils in unexposed individuals. 
SARS-CoV-2-specific mCD8+ T cells occur at similar 
frequencies and prevalence rates in oropharyngeal 
lymphoid tissue from unexposed children and adults 
Pre-existing immunity may explain why children are less 
susceptible to severe COVID-19 (34). We therefore evaluated 
virus-specific tonsillar mCD8+ T cell responses in young chil-
dren (age 2–5 years) and adults (age 28–67 years) (Fig. 2A). 
SARS-CoV-2-specific mCD8+ T cells were distributed similarly 
between groups in terms of frequency and overall prevalence, 
with the exception of responses directed against the spike 
protein, which occurred at lower magnitudes in children (Fig. 
2B, C). EBV-specific mCD8+ T cells were less common in chil-
dren (Fig. 2B), likely reflecting lower seroprevalence rates 
(35). Similarly, HCoV-OC43-specific mCD8+ T cells were un-
detectable in tonsil samples from children (Fig. 2B), con-
sistent with lower seroprevalence rates for HCoVs-OC43 and 
other HCoVs (Fig. 2D, Fig. S5A, Table S2). Of note, HCoV-
OC43-specific responses were also undetectable in some 
HCoV-OC43-seropositive adults (Fig. S5B), confirming the 
previously reported discordance between humoral and cellu-
lar immunity against HCoVs (36). 
The presence of EBV-specific mCD8+ T cell responses as-
sociated with the occurrence of SARS-CoV-2-specific mCD8+ 
T cell responses in children but not in adults (Table S3). In 
addition, the stimulation indices for mCD8+ T cell responses 
directed against the SARS-CoV-2 nucleocapsid, ORF1b, and 
ORF3–10 proteins correlated positively with certain HCoV-
specific antibody titers (Fig. 2E, Fig. S5C), and SARS-CoV-2-
specific mCD8+ T cell responses were identified only in chil-
dren with detectable antibodies specific for HKU-1 or NL63 
and not in children with detectable antibodies specific for 
229E or OC43 (Fig. S5D). No significant correlations were de-
tected between age and SARS-CoV-2-derived antigen-specific 
mCD8+ T cell response stimulation indices in children or 
adults (Fig. 2D). However, positive correlations were detected 
between mCD8+ T cell responses directed against nucleocap-
sid, ORF1a, and ORF3–10 in children, and nucleocapsid only 
in adults, and the overall size of the mCD8+ T cell pool (Figs. 
2E and S5C). Accordingly, previous exposure to other viruses, 
including HCoVs, not age, appeared to drive the formation of 
oropharyngeal mCD8+ T cell responses against SARS-CoV-2. 
SARS-CoV-2-specific mCD8+ T cells exhibit a follicu-
lar homing and TRM phenotype in oropharyngeal lym-
phoid tissue from unexposed individuals 
To extend these findings, we investigated the phenotypic 
characteristics of virus-specific mCD8+ T cells in the tonsils, 
with a particular focus on markers of follicular homing and 
tissue residency. Importantly, the expression of surface mark-
ers in this analysis, including CD69, was not influenced by 
stimulation in these experiments (Fig. S6A–C). mCD8+ T cells 
specific for different SARS-CoV-2-derived antigens were 
pooled for downstream analyses on the grounds of pheno-
typic homogeneity (Fig. S6D, E). 
Total and virus-specific mCD8+ T cells were concatenated 
from four representative individuals, and non-linear relation-
ships among individual cells were assessed using Uniform 
Manifold Approximation and Projection (UMAP) (Fig. 3A). 
Distinct topographical regions were delineated by overlaying 
the expression of analyzed phenotypic markers, namely 
CD103, CD49a, CD69, CCR6, CXCR5, PD-1, CXCR3, CCR7, and 
CD45RA (Fig. 3B). Phenograph analysis revealed 11 unique 
clusters in the UMAP space (Fig. 3C), each with a distinct pat-
tern of surface marker expression (Fig. 3D). Overlays of anti-
gen-specific mCD8+ T cells revealed unique clustering based 
on specificity (Fig. 3E). SARS-CoV-2-specific and EBV-specific 
mCD8+ T cells were found mainly in clusters 1, 3, and 9 (Fig. 
3G), which displayed high expression of the TRM markers 
CD103 and CD69 and the follicular homing marker CXCR5 
(Fig. 3B, D). In contrast, CMV-specific mCD8+ T cells were 
distributed among clusters 4 to 8, which included popula-
tions expressing high levels of CD45RA and populations lack-
ing CD103 and CXCR5 (Fig. 3B–G). HCoV-OC43-specific 
mCD8+ T cells were found predominantly in cluster 2, which 
displayed high expression levels of the TRM markers CD103, 
CD49a, and CD69. Manual gating analysis further confirmed 
these phenotypic differences among specificities with respect 
to CD103, CD69, and CXCR5 (Figs. 3H, I and S6F, G). SARS-
CoV-2-specific and EBV-specific tonsillar mCD8+ T cells were 
therefore characterized by a follicular homing and TRM phe-
notype, which was similar in children and adults (Fig. S6H, 
I). 
Functional properties of virus-specific mCD8+ T 
cells in oropharyngeal lymphoid tissue 
To assess the functionality of virus-specific tonsillar 
mCD8+ T cells, we quantified the surface mobilization of 
CD107a and the intracellular expression of TNF-α and IL-2 
alongside 4-1BB and IFN-γ in response to peptide stimulation 
(Fig. 4A). Pre-existing mCD8+ T cells specific for SARS-CoV-2 
mobilized CD107a and up-regulated TNF-α and IL-2 as indi-
vidual functions less commonly than mCD8+ T cells specific 
for EBV, CMV, or HCoV-OC43 (Fig. 4B). In addition, mCD8+ 
T cells specific for EBV, CMV, or HCoV-OC43 were highly 
polyfunctional and frequently expressed IFN-γ together with 
CD107a, TNF-α, and/or IL-2 (Figs. 4C and S7A), whereas 
mCD8+ T cells specific for SARS-CoV-2 were generally oligo-
functional (Figs. 4C and S7A) and expressed comparatively 
lower amounts of IFN-γ, TNF-α, and IL-2 on a per cell basis 
(Fig. 4D). A similar pattern of suboptimal functionality has 
been described previously for cross-reactive intravascular 
SARS-CoV-2-specific mCD4+ T cells, likely reflecting low-avid-
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Of note, mCD8+ T cells specific for each virus mobilized 
CD107a to a similar extent and produced largely equivalent 
amounts IFN-γ, TNF-α, and IL-2 on a per cell basis in chil-
dren and adults (Fig. S7B). The functional profiles of EBV-
specific and CMV-specific mCD8+ T cells were also similar in 
each group, although EBV-specific mCD8+ T cells more com-
monly produced IL-2 in adults (Fig. 4E). In contrast, SARS-
CoV-2-specific mCD8+ T cells more commonly mobilized 
CD107a and more commonly expressed other functional 
markers alongside IFN-γ in children (Figs. 4E and S7C). To-
gether, these data suggest that SARS-CoV-2-unexposed chil-
dren harbored higher frequencies of polyfunctional SARS-
CoV-2-reactive mCD8+ T cells in tonsillar lymphoid tissue 
compared with unexposed adults. 
DISCUSSION 
CD8+ T cells are essential for immune control and clear-
ance of previously encountered viruses. CD8+ T cells may also 
provide a degree of heterologous protection against previ-
ously unencountered viruses expressing structurally related 
or unrelated antigens that elicit functional responses within 
the pre-existing memory pool as a consequence of cross-reac-
tivity (37–39). In line with the concept of heterologous im-
munity, previous studies have demonstrated a high 
prevalence of SARS-CoV-2-specific mCD4+ T cells and a rela-
tive paucity of SARS-CoV-2-specific mCD8+ T cells in the pe-
ripheral blood of SARS-CoV-2-unexposed individuals (8–14). 
However, it has remained unclear to what extent such pre-
existing T cell responses against SARS-CoV-2 exist in tissues, 
which is an important omission especially given the critical 
role of anatomically localized immunity in other viral infec-
tions (25–27). The present study was designed to address this 
knowledge gap and provide a comprehensive picture of pre-
existing SARS-CoV-2-specific mCD4+ and mCD8+ T cell im-
munity in the tonsils, representing key lymphoid organs in 
the upper respiratory tract and the intravascular circulation. 
We found that SARS-CoV-2-specific mCD4+ T cells were dis-
tributed evenly between these compartments, whereas SARS-
CoV-2-specific mCD8+ T cells were almost exclusively present 
in the tonsils. Earlier studies confined to analyses of periph-
eral blood samples have therefore likely underestimated the 
overall prevalence of heterologous mCD8+ T cell responses 
against SARS-CoV-2. 
Tonsils play an important role in immune defense against 
inhaled or orally acquired pathogens, highlighted by the in-
creased risk of upper respiratory tract infections in children 
after tonsillectomy (40). Although much emphasis has been 
placed on the nasal/respiratory route of viral transmission 
(41), the oral cavity, including the tonsils, can also be infected 
and potentially acts as a primary site for the acquisition of 
SARS-CoV-2 (42). We found that SARS-CoV-2-specific mCD8+ 
T cells expressed markers of tissue residency, potentially 
forming a sentinel immune response at a key site of viral 
entry (27). Importantly, TRM cells function partly as innate-
like sensors (43) and may therefore trigger an early type I IFN 
response, which commonly associates with non-severe forms 
of COVID-19. Of note, an early CD8+ T cell proliferation sig-
nature coinciding with a type I IFN response has been de-
tected in asymptomatic and mild cases of COVID-19 before 
the detection of SARS-CoV-2 (44). This phenomenon associ-
ates with accelerated viral clearance and a less severe cyto-
kine storm at the site of infection, as demonstrated for cross-
reactive TRM cell responses directed against influenza virus, 
SARS-CoV-1, or Middle East respiratory syndrome-related 
coronavirus in mice (37, 45). It remains unclear whether such 
early activation of SARS-CoV-2-specific CD8+ T cells reflects 
pre-existing memory recall or rapid de novo priming from the 
naive pool in milder forms of COVID-19. However, recent in-
fection with HCoVs associates with less severe disease and 
lower mortality rates after subsequent infection with SARS-
CoV-2 (17). In addition, pre-existing virus-specific mCD4+ and 
mCD8+ T cells numerically expand in the peripheral blood af-
ter infection with SARS-CoV-2 (46, 47), and more robust cel-
lular and humoral immune responses occur after infection in 
patients with pre-existing CD4+ T cell responses directed 
against SARS-CoV-2 (18). Further studies incorporating 
larger numbers of patients, matched tissue samples, and lon-
gitudinal analyses will nonetheless be required to understand 
the full impact of pre-existing SARS-CoV-2-specific mCD4+ 
and mCD8+ T cell responses on the outcome of COVID-19. 
EBV-specific mCD8+ T cells preferentially localized to the 
tonsils, where they exhibited a follicular homing and TRM phe-
notype akin to SARS-CoV-2-specific mCD8+ T cells, whereas 
CMV-specific mCD8+ T cells, which mostly lacked TRM mark-
ers, are largely confined to the intravascular circulation (33). 
This anatomical dichotomy makes sense biologically, given 
the distinct tropism patterns of EBV and CMV with EBV be-
ing transmitted orally and mainly infecting B lymphocytes 
residing in lymphoid tissues and epithelial cells and CMV 
spreading throughout the body to infect multiple cell types 
and organs. CD69+CD103+ tonsillar mCD8+ T cells are located 
near the epithelial barrier surface, likely facilitated by high 
expression levels of E-cadherin (33). Accordingly, the pre-ex-
isting SARS-CoV-2-specific tonsillar mCD8+ T cells identified 
here might have been positioned near sites of viral entry, po-
tentially enabling them to spearhead an early immune re-
sponse. 
Children and young adults are less prone to severe 
COVID-19 than older adults (48). Although there is a decline 
in cross-reactive SARS-CoV-2-specific humoral and cellular 
immunity with age (49, 50), we found that pre-existing SARS-
CoV-2-specific tonsillar mCD8+ T cells in children and adults 
were similar in terms of frequency, phenotype, and overall 
prevalence. It is notable that we did not detect HCoV-OC43-
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children, despite the fact that some of these individuals were 
HCoV-OC43-seropositive and/or harbored detectable mCD4+ 
T cell responses directed against HCoV-OC43. This discrep-
ancy could reflect sensitivity limitations in our approach to 
the detection of antigen-specific mCD8+ T cells directly ex 
vivo. In addition, HCoV-specific mCD8+ T cell responses may 
be liable to decay (51), and repeated viral exposure may be 
necessary to induce long-lived HCoV-specific CD8+ TRM cells 
(52). A similar discrepancy is reported in a study of peripheral 
blood samples comparing cellular and humoral responses 
against HCoVs (36). 
It is likely that pre-existing SARS-CoV-2-specific mCD4+ 
and mCD8+ T cell immunity is generated via previous en-
counters with HCoVs. In line with this notion, we found that 
SARS-CoV-2-specific mCD8+ T cell response frequencies cor-
related with certain HCoV-specific antibody titers, and in 
children, we identified SARS-CoV-2-specific mCD8+ T cell re-
sponses almost exclusively in individuals with detectable an-
tibodies specific for HCoV-HKU-1 or HCoV-NL63. However, 
we also found that the presence of EBV-specific mCD8+ T cell 
responses in children, likely reflecting persistent infection, 
associated with the occurrence of SARS-CoV-2-specific 
mCD8+ T cell responses potentially arising as a consequence 
of heterologous immunity (38). Alternatively, the presence of 
EBV-specific mCD8+ T cell responses could identify children 
with greater overall levels of exposure to endemic pathogens. 
Consistent with either possibility, the stimulation indices for 
some SARS-CoV-2-specific mCD8+ T cell responses correlated 
with the overall size of the mCD8+ T cell pool, which provides 
a general measure of immunological experience (6). Accord-
ingly, prior antigen experience is likely the key driver of het-
erologous immunity, irrespective of the precise mechanism, 
shaping a diverse repertoire of mCD8+ T cells incorporating 
various specificities with the ability to cross-recognize SARS-
CoV-2. 
Overall, we detected SARS-CoV-2-specific mCD4+ T cell re-
sponses in 29% of unexposed peripheral blood samples, 
which is within the range reported previously (8–14). How-
ever, the true prevalence may be higher, because recovered 
cell numbers in some cases precluded a full assessment of all 
viral antigen specificities. A similar caveat applies to the iden-
tification of SARS-CoV-2-specific mCD8+ T cell responses in 
peripheral blood samples and the identification of SARS-CoV-
2-specific mCD4+ and mCD8+ T cell responses in the tonsils. 
In addition, our study was limited by detection based on the 
production of IFN-γ or TNF-α, which excluded cells that did 
not produce these cytokines in response to antigen encoun-
ter. Furthermore, a high level of background activation with-
out any peptide stimulation in some individuals may prevent 
the detection of low frequency virus-specific T cell responses. 
It should also be noted that our findings cannot be taken in 
isolation as evidence of heterologous immune protection 
against SARS-CoV-2. 
In summary, we have shown that SARS-CoV-2-unexposed 
children and adults commonly harbor tonsillar CD8+ TRM cells 
that react with SARS-CoV-2. Additional studies are now war-
ranted to determine if these pre-existing CD8+ TRM cells lead 
to early viral containment, potentially mitigating the course 
of COVID-19. 
MATERIALS AND METHODS 
Study design 
The objective of this study was to characterize SARS-CoV-
2-reactive mCD4+ and mCD8+ T cell responses in tonsillar 
lymphoid tissue and matched peripheral blood samples ob-
tained from children and adults prior to the current pan-
demic between 2015 and 2018. Functional and phenotypic 
analyses were extended for comparative purposes to include 
mCD4+ and mCD8+ T cell responses elicited by natural infec-
tions with EBV, CMV, and HCoV-OC43. 
Human subjects and ethics 
Tonsil samples and matched peripheral blood mononu-
clear cells (PBMCs) were obtained from individuals undergo-
ing tonsillectomy for obstructive sleep apnea at the 
Department of Otorhinolaryngology, Karolinska University 
Hospital, Stockholm, Sweden. All samples were collected be-
tween 2015 and 2018. The study was approved by the regional 
ethics committee in Stockholm (2014/1000-31 for the child 
cohort and 2015/755-31, 2016/128-32, and 2017/2275-32 for 
the adult cohort). Written informed consent was obtained 
from all participants or their legal representatives in accord-
ance with the Declaration of Helsinki. Whole tonsils were cut 
into small pieces, ground through a cell strainer (pore size = 
100 μm), filtered through another cell strainer (pore size = 40 
μm), and resuspended in phosphate-buffered saline (PBS). 
Mononuclear cells were isolated via standard density gradi-
ent centrifugation and cryopreserved in fetal bovine serum 
(FBS) containing 10% dimethyl sulfoxide (DMSO). PBMCs 
were isolated and cryopreserved similarly. Plasma samples 
were collected from some individuals (n = 21 children and n 
= 12 adults) and stored at −80°C. The adult tonsil cohort was 
dominated by male participants in this study, because ob-
structive sleep apnea is more common in adult men than in 
adult women (53). Plasma samples were also collected from 
two convalescent individuals recovering from infection with 
SARS-CoV-2 (Ethical approval: dnr 2019-05757 and dnr 
2014/1000-31/1) and stored at −80°C. Donor characteristics 
are summarized in Table S1. 
Peptides 
Lyophilized pools of overlapping peptides spanning the 
relevant proteins were reconstituted in DMSO and further di-
luted to 50 or 100 μg/ml in PBS. Reconstituted pools were 
aliquoted and stored at −20°C. Overlapping peptide pools 
spanning the SARS-CoV-2 spike (Prot_S) and nucleocapsid 
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Overlapping peptide pools spanning the SARS-CoV-2 mem-
brane and envelope (Membrane+Env) proteins and the 
ORF3A, ORF6, ORF7A, ORF8, and ORF10 (ORF3–10) proteins 
were synthesized using sequences derived from GenBank ref-
erence MT093571.1 (Sigma-Aldrich). Overlapping peptide 
pools spanning the SARS-CoV-2 ORF1a and ORF1b proteins 
were generated by combining NSP1–11 and NSP12–16, respec-
tively (JPT Peptide Technologies). Overlapping peptide pools 
spanning the EBV BZLF1, EBNA-1, EBNA-3a, and LMP2 pro-
teins were purchased from JPT Peptide Technologies. Over-
lapping peptide pools spanning the CMV pp65 and IE-1 
proteins were purchased from Peptides & Elephants. 
Metadata for all available OC43 sequences on ViPR were 
downloaded on January 27, 2020. Sequences were filtered to 
include isolates from humans and exclude isolates from cell 
passage or vaccine development studies. One sequence per 
country per year was selected to create a representative set of 
OC43 sequences. The spike, nucleocapsid, and membrane 
gene amino acid translations (as available) were downloaded 
from GenBank. The amino acid sequences for each gene were 
then translated using the ‘–auto’ setting in MAFFT (54), and 
a consensus sequence for each gene was generated using the 
‘dump_consensus()’ method with default settings in BioPy-
thon (55). Overlapping peptide pools spanning these HCoV-
OC43 spike, nucleocapsid, and membrane (OC43) protein 
consensus sequences were synthesized by Sigma-Aldrich. The 
relevant peptides were combined to generate single pools for 
EBV, CMV, and HCoV-OC43. 
Intracellular cytokine staining 
Cryopreserved tonsil cells and PBMCs were thawed 
quickly, resuspended in RPMI 1640 containing 10% FBS, 1% 
L-glutamine, and 1% penicillin/streptomycin (complete me-
dium) in the presence of DNase I (10 U/ml; Sigma-Aldrich), 
and rested at 1–2 × 106 cells/well in 96-well U-bottom plates 
(Corning) for 5 hours at 37°C. The medium was then supple-
mented with anti-CXCR5–BB515 (clone RF8B2; BD Biosci-
ences), followed 15 min later by the relevant peptide pools 
(0.5 μg/ml/peptide), and a further 1 hour later by brefeldin A 
(1 μg/ml; Sigma-Aldrich), monensin (0.7 μg/ml; BD Biosci-
ences), and anti-CD107a–BV785 (clone H4A3; BioLegend). In 
one experiment, tonsil cells were stained with anti-CD69–
BUV563 (clone FN50; BD Biosciences) for 30 min at room 
temperature and washed in complete medium before stimu-
lation (Fig. S6A). Negative control wells contained equivalent 
DMSO, and positive control wells contained staphylococcal 
enterotoxin B (SEB; 0.5 μg/ml; Sigma-Aldrich). After 9 hours, 
cells were washed in PBS supplemented with 2% FBS and 2 
mM EDTA (FACS buffer) and stained with anti-CCR4–BB700 
(clone 1G1; BD Biosciences), anti-CCR6–BUV737 (clone 11A9; 
BD Biosciences), anti-CCR7–APC-Cy7 (clone G043H7; Bio-
Legend), and anti-CXCR3–BV750 (clone 1C6; BD Biosciences) 
for 10 min at 37°C. Additional surface stains were performed 
for 30 min at room temperature in the presence of Brilliant 
Stain Buffer Plus (BD Biosciences). Viable cells were identi-
fied by exclusion using a LIVE/DEAD Fixable Aqua Dead Cell 
Stain Kit (Thermo Fisher Scientific). Cells were then washed 
in FACS buffer and fixed/permeabilized using a FoxP3 Tran-
scription Factor Staining Buffer Set (Thermo Fisher Scien-
tific). Intracellular stains were performed for 30 min at room 
temperature. Stained cells were washed in FACS buffer, fixed 
in PBS containing 1% paraformaldehyde (PFA; Biotium), and 
acquired using a FACSymphony A5 (BD Biosciences). Flow 
cytometry reagents are listed in Table S4. 
Surface staining for activation-induced markers 
Cryopreserved tonsil cells and PBMCs were thawed 
quickly, resuspended in complete medium in the presence of 
DNase I (10 U/ml; Sigma-Aldrich), and rested at 1–2 × 106 
cells/well in 96-well U-bottom plates (Corning) for 5 hours at 
37°C. The medium was then supplemented with the relevant 
peptide pools (0.5 μg/ml/peptide). Negative control wells 
contained equivalent DMSO, and positive control wells con-
tained staphylococcal enterotoxin B (SEB; 0.5 μg/ml; Sigma-
Aldrich). After 18 hours, cells were washed in FACS buffer 
and stained with anti-CCR7–APC-Cy7 (clone G043H7; Bio-
Legend) for 10 min at 37°C. Additional surface stains were 
performed for 30 min at room temperature in the presence 
of Brilliant Stain Buffer Plus (BD Biosciences). Viable cells 
were identified by exclusion using a LIVE/DEAD Fixable 
Aqua Dead Cell Stain Kit (Thermo Fisher Scientific). Stained 
cells were washed in FACS buffer, fixed in PBS containing 1% 
PFA (Biotium), and acquired using a FACSymphony A5 (BD 
Biosciences). Flow cytometry reagents are listed in Table S4. 
Human coronavirus serology 
Stored plasma samples were thawed on ice and centri-
fuged at 10,000 × g for 10 min. Human coronavirus antibody 
concentrations were analyzed using a ProcartaPlex Human 
Coronavirus Ig Total 11-Plex Panel (Thermo Fisher Scientific). 
Fluorescence was determined using a Bio-Plex MAGPIX Mul-
tiplex Reader (Bio-Rad). 
Tetramer staining 
Cryopreserved tonsil cells were thawed quickly, washed in 
PBS, distributed at 1–2 × 106 cells/well in 96-well U-bottom 
plates (Corning), and stained with anti-CCR7–APC-Cy7 (clone 
G043H7; BioLegend) for 10 min at 37°C. Cells were then la-
beled with a mix of BV421-conjugated human leukocyte anti-
gen (HLA) class I tetramers for 15 min at room temperature 
in the presence of dasatinib (50 nM; STEMCELL). The follow-
ing tetramers were used in these experiments, each corre-
sponding to a defined epitope derived from EBV: 
GLCTLVAML/HLA-A*02:01, TYGPVFMCL/HLA-A*24:02, 
RPPIFIRRL/HLA-B*07:02, and RAKFKQLL/HLA-B*08:01 
(56). Additional surface stains were performed for 30 min at 
4°C. Viable cells were identified by exclusion using a 
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Scientific). Stained cells were washed in FACS buffer, fixed in 
PBS containing with 1% PFA (Biotium), and acquired using a 
FACSymphony A5 (BD Biosciences). Flow cytometry reagents 
are listed in Table S4. 
Data analysis and statistics 
Flow cytometry data were analyzed using FlowJo software 
version 10.7.1 (FlowJo LLC). The gating strategy is shown in 
Fig. S1. Net frequencies of virus-specific T cells were calcu-
lated by subtracting the frequency of specific marker+ T cells 
in the negative control from the frequency of specific marker+ 
T cells detected after stimulation with each peptide pool, with 
negative values set to 0. Stimulation indices were calculated 
as fold change. Positive responses required a stimulation in-
dex ≥2 and a minimum of 5 cells in the specific marker+ gate 
as described previously (30, 57). Only responses assigned as 
positive based on these criteria were included in downstream 
analyses to limit the impact of background noise. Stimulation 
indices were only included if the calculations were based on 
>5 cells in each marker+ population. Dimensionality reduc-
tion was performed using the FlowJo plugin UMAP version 
3.1 (FlowJo LLC). Downsampled files concatenated from rep-
resentative donors (n=4) were used for these analyses with 
default settings (distance function: Euclidean; nearest neigh-
bors: 15; minimum distance: 0.5) for the indicated markers 
(Fig. 3). Clusters of phenotypically related cells were identi-
fied using the FlowJo plugins PhenoGraph version 3.0 and 
Violinbox version 5.1.8 (FlowJo LLC). 
Human coronavirus antibody concentrations were calcu-
lated using standard curves for relative quantitative results 
in units/ml using Bio-Plex Manager Software version 6.1 (Bio-
Rad). Values below the standard range were set to the lowest 
standard concentration. The seropositivity threshold applied 
to all Ig measurements was established using the following 
formula: mean concentration of SARS-CoV-2 trimer Ig for un-
exposed individuals + (3 * standard deviation) (58), which 
provided an estimated specificity of 99%. 
Statistical analyses were performed using Prism version 9 
for macOS (GraphPad Software Inc.). Significance between 
two paired groups was assessed using the Wilcoxon signed 
rank test, and significance between two unpaired groups was 
assessed using the Mann-Whitney test. Significance among 
three or more unpaired groups or among paired groups with 
missing values was assessed using the Kruskal-Wallis test 
with Dunn’s post-test. Categorical variables were compared 
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Fig. 1. Identification of tonsillar mCD8+ T cells specific for SARS-CoV-2 in unexposed individuals. Tonsil cells from 
children (n = 40) and adults (n = 41) were stimulated with overlapping peptide pools and analyzed for intracellular 
expression of 4-1BB/IFN-γ. (A) Representative plots showing the gating of 4-1BB+IFN-γ+ mCD8+ T cells from 
individuals with responses to several SARS-CoV-2 proteins (top) or one SARS-CoV-2 protein (bottom). (B) Net 
frequencies (background subtracted) of 4-1BB+IFN-γ+ mCD8+ T cells. (C) Stimulation indices for 4-1BB+IFN-γ+ mCD8+ 
T cells calculated as fold change relative to the negative control. The dotted line indicates a stimulation index of 2. (D) 
Frequency of tonsil samples with positive antigen-specific mCD8+ T cell responses (stimulation index ≥2). (E) 
Correlation matrix showing associations between stimulation indices for virus-specific mCD8+ T cells. (F) 
Representative gating of 4-1BB+IFN-γ+ mCD8+ T cells in matched blood and tonsil samples. (G) Frequencies of 4-
1BB+IFN-γ+ mCD8+ T cells in matched blood and tonsil samples. (H) Frequency of blood or tonsil samples with positive 
mCD4+ or mCD8+ T cell responses to SARS-CoV-2. (B–E) S: spike; NC: nucleocapsid; M+E: membrane+envelope. (B, 
C) Graphs show median ± IQR. Kruskal-Wallis test with Dunn’s post-test. (E) Spearman correlations. (G) Wilcoxon 
















Fig. 2. Magnitude and prevalence of tonsillar mCD8+ T cells specific for SARS-CoV-2 in unexposed children 
and adults. Virus-specific tonsillar mCD8+ T cell responses were compared between children (white 
bars/symbols; n = 40) and adults (grey bars/symbols; n = 41). (A) Overall frequency of tonsil samples tested 
with individual peptide pools. (B) Overall frequency of tonsil samples with positive mCD8+ T cell responses 
(stimulation index ≥2) to different antigens. (C) Stimulation indices for 4-1BB+IFN-γ+ mCD8+ T cells calculated as 
fold change relative to the negative control. The dotted line indicates a stimulation index of 2. (D) Antibody titers 
(U/ml) for HCoVs in children (n = 21) and adults (n = 12). The dotted line represents a seropositivity threshold 
calculated on the basis of SARS-CoV-2 spike trimer-specific antibody titers as shown in Fig. S5A. (E) Correlation 
matrices showing associations between stimulation indices for SARS-CoV-2-specific mCD8+ T cell responses, 
HCoV antibody titers, age, and total frequencies of mCD8+ T cells for children, adults, or both cohorts. (A–C) S: 
spike; NC: nucleocapsid; M+E: membrane+envelope. (B) Fisher’s exact test. (C, D) Graphs show median ± IQR. 
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Fig. 3. Tonsillar SARS-CoV-2-specific mCD8+ T cells in unexposed individuals express CD103, CD69, 
and CXCR5. (A) UMAP representation showing the clustering of concatenated total and virus-specific 
mCD8+ T cells from representative individuals (n = 4). (B) Expression of individual surface markers overlaid 
on the UMAP plot derived from (A). (C) UMAP representation derived from (A) with subpopulations (n = 11) 
identified using Phenograph. (D) Hierarchical clustering of expression intensity for the indicated markers 
in each subpopulation identified in (C). (E) Distribution of virus-specific mCD8+ T cells on the UMAP plot 
derived in (A). (F) Median percent expression of the indicated markers among virus-specific mCD8+ T cells. 
(G) Distribution of virus-specific mCD8+ T cells among clusters derived using Phenograph. Clusters are 
hierarchical as indicated in (D). (H) Frequency of CXCR5+ virus-specific mCD8+ T cells. (I) Comparison of 
virus-specific mCD8+ subsets based on the expression of CD69/CD103. (H, I) Graphs show median ± IQR. 















Fig. 4. Functional profiles of virus-specific tonsillar mCD8+ T cells. (A) Representative plots showing coexpression 
of CD107a/TNF-α or IL-2/TNF-α among 4-1BB+IFN-γ+ virus-specific mCD8+ T cells. (B) Frequencies of CD107a+, TNF-
α+, or IL-2+ virus-specific mCD8+ T cells. (C) Pie chart summarizing the functional profiles of virus-specific mCD8+ T 
cells. (D) Geometric mean (GeoMean) fluorescence values for IFN-γ, CD107a, TNF-α, and IL-2 among function+ virus-
specific mCD8+ T cells. (E) Functional profiles and frequencies of CD107a+, TNF-α+, or IL-2+ virus-specific mCD8+ T 
cells in children and adults. Graphs show median (C, E) or median ± IQR (B, D, E). (B, D) Kruskal-Wallis test with Dunn’s 
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